T
Tianshu Liu
Researcher at Fudan University
Publications - 97
Citations - 2180
Tianshu Liu is an academic researcher from Fudan University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 18, co-authored 93 publications receiving 1129 citations.
Papers
More filters
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
TL;DR: The molecular functions of EZH2 are discussed, recent findings regarding the physiological functions and related regulation of E zeste homolog 2 in cancer pathogenesis are highlighted, and the emerging roles of EzH2 in tumor immunity are summarized.
Journal ArticleDOI
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu,Tae-Won Kim,Lin Shen,Virote Sriuranpong,Hongming Pan,Rui-Hua Xu,Weijian Guo,Sae-Won Han,Tianshu Liu,Young Suk Park,Chunmei Shi,Yuxian Bai,Feng Bi,Joong Bae Ahn,Shukui Qin,Qi Li,Changping Wu,Dong Ma,Donghu Lin,Donghu Lin,Donghu Lin,Jin Li,Jin Li,Jin Li +23 more
TL;DR: Trifluridine/tipiracil has a statistically significant survival benefit compared with placebo in Asian patients with mCRC refractory or intolerant to standard chemotherapies, regardless of exposure to biologic therapy.
Journal ArticleDOI
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Shukui Qin,Jin Li,Liwei Wang,Jianming Xu,Ying Cheng,Yuxian Bai,Wei Li,Nong Xu,Lizhu Lin,Qiong Wu,Yunfeng Li,Jianwei Yang,Hongming Pan,Xuenong Ouyang,Wensheng Qiu,Kaichun Wu,Jianping Xiong,Guanghai Dai,Houjie Liang,Chunhong Hu,Zhang Jun,Min Tao,Qiang Yao,Junyuan Wang,Jiongjie Chen,S. Peter Eggleton,Tianshu Liu +26 more
TL;DR: The TAILOR study met all of its objectives and relevant clinical end points, confirming cetuximab in combination with FOLFOX as an effective standard-of-care first-line treatment regimen for patients with RAS wt mCRC.
Journal ArticleDOI
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Jianming Xu,Lin Shen,Zhiwei Zhou,Jie Li,Chunmei Bai,Yihebali Chi,Zhiping Li,Nong Xu,Enxiao Li,Tianshu Liu,Yuxian Bai,Ying Yuan,Xingya Li,Xiuwen Wang,Jia Chen,Jieer Ying,Xianjun Yu,Shukui Qin,Xianglin Yuan,Tao Zhang,Yanhong Deng,Dianrong Xiu,Ying Cheng,Min Tao,Ru Jia,Wei Wang,Jing Li,Songhua Fan,Mengye Peng,Weiguo Su +29 more
TL;DR: Progression-free survival was significantly longer in patients given surufatinib compared with patients given placebo, and surfatinib has a favourable benefit-to-risk profile in patients with progressive, advanced, well differentiated extrapancreatic NETs.